ScreenerHero

CRVS Corvus Pharmaceuticals, Inc.

NAS · US · Healthcare · Biotechnology · corvuspharma.com
10.41USD-1.42%Mkt Cap: 875.70M $P/E: —

Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, engages in the development of product candidates that precisely target proteins that are critical to immune cell maturation and function in the Un…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$128.08BUSDP/E 29.4
MRNA
Moderna, Inc.
$78.44BUSD
REGN
Regeneron Pharmaceuticals, Inc.
$76.40BUSDP/E 18.4
ARGX
argenx SE
$57.03BUSDP/E 37.3
ARGX
argenx SE
$58.08BUSDP/E 35.4
UCB
UCB SA
$42.24BUSDP/E 18.0
RVMD
Revolution Medicines, Inc.
$43.05BUSD
ONC
BeOne Medicines AG
$41.41BUSDP/E 65.1
RPRX
Royalty Pharma plc
$32.80BUSDP/E 30.2
ALNY
Alnylam Pharmaceuticals, Inc.
$30.03BUSDP/E 37.8
ROIV
Roivant Sciences Ltd.
$25.10BUSD
BNTX
BioNTech SE
$23.93BUSD
INCY
Incyte Corporation
$22.99BUSDP/E 14.5
GMAB
Genmab A/S
$22.27BUSDP/E 30.7
GMAB
Genmab A/S
$22.54BUSDP/E 28.9
INSM
Insmed Incorporated
$22.22BUSD
ASND
Ascendis Pharma A/S
$15.03BUSDP/E 17.5
JAZZ
Jazz Pharmaceuticals plc
$15.01BUSDP/E 15.8
EXEL
Exelixis, Inc.
$14.48BUSDP/E 18.4
SMMT
Summit Therapeutics Inc.
$14.32BUSD

Key Statistics

Company
Market Cap875.70M USD
Enterprise Value673.82M USD
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-15.28M USD
Revenue/Share—
Last Price10.41 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees37
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-9.89
PEG—
EV/EBITDA-11.85
EV/Revenue—
P/S—
P/B3.94
EPS (TTM)-0.61
EPS (Forward)-1.07
52W Range
6.31520% of range26.95
52W High26.95 USD
52W Low6.315 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-24.97%
ROA-21.49%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-32.80M USD
CapEx (TTM)174.00K USD
FCF Margin—
FCF Yield-3.13%
Net Debt-214.50M USD
Net Debt/EBITDA3.77
Balance Sheet
Debt/Equity0.02
Current Ratio16.16
Quick Ratio15.88
Book Value/Sh2.68 USD
Cash/Share2.56 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.1 (Strong Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)33.14 USD
Upside (mean)+218.4%
Target Range27.00 USD – 42.00 USD
27.00+218.4% to mean42.00
# Analysts7
Ownership
Shares Out.84.12M
Float72.79M
Insiders3.51%
Institutions85.82%
Short Interest
Short Ratio21.5d
Short % Float23.21%
Short % Out.20.42%
Shares Short17.18M
Short (prev mo.)19.13M
Technical
SMA 5013.44 (-22.6%)
SMA 20014.17 (-26.5%)
Beta1.43
S&P 52W Chg16.45%
Avg Vol (30d)1.04M
Avg Vol (10d)1.04M
Technical Indicators
RSI (14)27.5
MACD-0.8562
MACD Signal-0.6932
MACD Hist.-0.1630
BB Upper14.21 USD
BB Middle12.11 USD
BB Lower10.01 USD
BB Width34.70%
ATR (14)0.6959 USD
Vol Ratio (20d)0.95x